Multiple Myeloma

GSK cancer drug Blenrep gets surprise trial win
GSK cancer drug Blenrep gets surprise trial win
BioPharma Dive
GSK
Blenrep
clinical trials
Multiple Myeloma
Flag link:
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting
BioSpace
Legend Biotech
Multiple Myeloma
cilta-cel
ASH 2023
Flag link:
After launch limitations, Johnson & Johnson exec touts manufacturing progress on CAR-T drug Carvykti
After launch limitations, Johnson & Johnson exec touts manufacturing progress on CAR-T drug Carvykti
Fierce Pharma
JNJ
Legend Biotech
Multiple Myeloma
CAR-T
Carvykti
cell therapy
Flag link:
5 FDA decisions to watch in the fourth quarter
5 FDA decisions to watch in the fourth quarter
BioPharma Dive
FDA
Alnylam
Onpattro
ATTR amyloidosis
Vertex Pharmaceuticals
CRISPR Therapeutics
exa-cel
Bluebird Bio
Zynteglo
sickle cell disease
Bristol Myers Squibb
2seventy bio
Abecma
Multiple Myeloma
Amgen
Lumakras
non-small cell lung cancer
Pfizer
estrasimod
ulcerative colitis
Flag link:
AbbVie’s venetoclax fails Phase III myeloma trial
AbbVie’s venetoclax fails Phase III myeloma trial
Clinical Trials Arena
AbbVie
venetoclax
Multiple Myeloma
clinical trials
Flag link:
In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset
In label expansion bid, AbbVie and Roche's Venclexta falls short in multiple myeloma subset
Fierce Pharma
AbbVie
Roche
Venclexta
Multiple Myeloma
Flag link:
J&J shines light on key role in multiple myeloma care team, vowing to raise awareness and offer support
J&J shines light on key role in multiple myeloma care team, vowing to raise awareness and offer support
Fierce Pharma
JNJ
Multiple Myeloma
pharma marketing
Flag link:
AbbVie Passes on License Option for Harpoon’s TriTAC Multiple Myeloma Program
AbbVie Passes on License Option for Harpoon’s TriTAC Multiple Myeloma Program
BioSpace
AbbVie
Harpoon Therapeutics
HPN217
Multiple Myeloma
Flag link:
BMS publishes 'modest' multiple myeloma survival data on heir to Revlimid, Pomalyst
BMS publishes 'modest' multiple myeloma survival data on heir to Revlimid, Pomalyst
Fierce Biotech
Bristol Myers Squibb
Revlimid
Pomalyst
Multiple Myeloma
mezigdomide
Flag link:
FDA approves bispecific drug from Pfizer for multiple myeloma
FDA approves bispecific drug from Pfizer for multiple myeloma
BioPharma Dive
Pfizer
bispecifics
Elrexfio
Multiple Myeloma
FDA
Flag link:
Pfizer pours $25M investment into Caribou's cell therapies
Pfizer pours $25M investment into Caribou's cell therapies
Fierce Biotech
Pfizer
Caribou Biosciences
gene editing
CAR-T
Multiple Myeloma
Flag link:
EHA 2023: Janssen’s talquetamab shows promise in multiple myeloma
EHA 2023: Janssen’s talquetamab shows promise in multiple myeloma
Clinical Trials Arena
talquetamab
JNJ
Multiple Myeloma
Flag link:
J&J sees trial data supporting earlier CAR-T use in multiple myeloma
J&J sees trial data supporting earlier CAR-T use in multiple myeloma
BioPharma Dive
ASCO 2023
JNJ
Legend Biotech
Carvykti
CAR-T
Multiple Myeloma
Flag link:
After FDA's delayed hold for multiple myeloma drug, Molecular Templates is back in action
After FDA's delayed hold for multiple myeloma drug, Molecular Templates is back in action
Fierce Biotech
Molecular Templates
clinical trials
MT-0169
FDA
Multiple Myeloma
Flag link:
J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows
J&J, Legend's Carvykti cut risk of progression or death by whopping 74% in earlier myeloma, leaked abstract shows
Fierce Pharma
CAR-T
Bristol Myers Squibb
JNJ
Legend Biotech
AACR
Multiple Myeloma
Carvykti
Abecma
Flag link:
Caribou gets FDA fast track for allogeneic CAR-T
Caribou gets FDA fast track for allogeneic CAR-T
Biopharma Reporter
Caribou Biosciences
FDA
Multiple Myeloma
CAR-T
CB-011
Flag link:
FDA places partial hold on Molecular Templates’ Phase I trial
FDA places partial hold on Molecular Templates’ Phase I trial
Clinical Trials Arena
Molecular Templates
MT-0169
Multiple Myeloma
clinical trials
Flag link:
This Cancer Drug Candidate Could Be a Hit for Pfizer
This Cancer Drug Candidate Could Be a Hit for Pfizer
Motley Fool
Pfizer
elranatamab
Multiple Myeloma
Flag link:
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down
Bristol Myers details landmark Abecma multiple myeloma data that ASH turned down
Fierce Pharma
Bristol Myers Squibb
Abecma
CAR-T
Multiple Myeloma
Flag link:
J&J, Legend’s cancer cell therapy has early success in key clinical trial
J&J, Legend’s cancer cell therapy has early success in key clinical trial
BioPharma Dive
JNJ
Legend Biotech
Carvykti
Multiple Myeloma
clinical trials
cell therapy
Flag link:

Pages